2007 JASN IMPACT FACTOR 7.111	HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP
advanced	CURRENT ISSUE	ARCHIVES	JASN Express	ONLINE SUBMISSION

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Molitch, M. E. Articles by Knowler, W. C. Search for Related Content PubMed PubMed Citation Articles by Molitch, M. E. Articles by Knowler, W. C.

The Diabetes Prevention Program and Its Global Implications

Mark E. Molitch^*, Wilfred Fujimoto, Richard F. Hamman and William C. Knowler for the Diabetes Prevention Program Research Group

Center for Endocrinology, Metabolism and Molecular Medicine, Northwestern University, The Feinberg School of Medicine, ¹Center for Endocrinology, Metabolism and Molecular Medicine, Northwestern, Chicago, Illinois; Department of Medicine, University of Washington School of Medicine, Seattle, Washington; Department of Preventive Medicine and Biometrics, University of Colorado Health Sciences Center, Denver, Colorado; Diabetes and Arthritis Epidemiology Section, National Institute of Diabetes and Digestive and Kidney Diseases, Phoenix, Arizona.

Correspondence to Dr. Mark E. Molitch, Diabetes Prevention Program Coordinating Center, Biostatistics Center, George Washington University, 6110 Executive Blvd., Suite 750, Rockville, MD 20852. Phone: 312-503-4130; Fax: 312-908-9032;

ABSTRACT. Type 2 diabetes affects over 150 million adults worldwide and this figure is expected to double over the next 25 yr. This increase will be accompanied by a marked increase in the number of patients with ESRD due to diabetes. We hypothesized that a lifestyle-intervention program or the administration of metformin would prevent or delay the development of diabetes We randomly assigned 3234 nondiabetic persons with elevated fasting and postload plasma glucose concentrations to placebo, metformin (850 mg twice daily), or a lifestyle-modification program with the goals of at least a 7% weight loss and at least 150 min of physical activity per week. The mean age of the participants was 51 yr, and the mean body mass index was 34.0 kg/m²; 68% were women, and 45% were members of non-Caucasian racial/ethnic groups. The average follow-up was 2.8 yr. The incidence of diabetes was 11.0, 7.8, and 4.8 cases per 100 person-years in the placebo, metformin, and lifestyle groups, respectively. The lifestyle intervention reduced the incidence of diabetes by 58% (95% CI: 48 to 66%) and metformin by 31% (95% CI: 17 to 43%), compared with placebo; the lifestyle intervention was significantly more effective than metformin. In conclusion, lifestyle changes and treatment with metformin both reduced the incidence of diabetes in persons at high risk and the lifestyle intervention was more effective than metformin. Because the lifestyle changes worked equally in all racial/ethnic groups in the Diabetes Prevention Program, they should be applicable to high-risk populations worldwide and may be able to reduce the projected progressive rise in the incidence of diabetes and the expected increase in ESRD. E-mail: dppmail@biostat.bsc.gwu.edu

This article has been cited by other articles:

				L. R. Hardy and R. A. Bell An Epidemiological Perspective on Type 2 Diabetes Among Adult Men Diabetes Spectr, October 1, 2004; 17(4): 208 - 214. [Abstract] [Full Text] [PDF]

Copyright © 2008 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673